Michael Wong

Jennifer Breheny Wallace, award-winning journalist and author, notes that C-Suite leaders should understand the financial risks of not taking action to address workplace burnout in 2024.

An overview of what biopharma C-Suites and their boards should consider when engaging with government and business leaders from China, the world’s second largest economy.

C-Suites and their boards should remember that digital transformation is a key part of the larger focus of a profound business transformation.

In this latest Harvard Business School Healthcare Alumni Association Q&A, JT Saunders, Chief Diversity Officer at global consulting firm Korn Ferry, discusses diversity in pharma, as well as what mentors and mentees should be considering in the workplace.

Author Deepa Purushothaman discusses the progress of women and women of color in corporate America.

Angie Lindsey, vice president of marketing, Fresenius Kabi USA shares 2023 strategies for talent management strategies in life sciences, specifically as it relates to sales and marketing.

Michael Ku, VP of global clinical supply at Pfizer, shares insights for the c-suite as well as reveals behind-the-scenes insight into Pfizer’s ability to deliver a COVID-19 vaccine swiftly.

Professor Nalebuff discusses the importance of negotiating and understanding what's actually at stake.

Pfeffer discusses his seven rules for power.

Hill shares her insights on what is needed for a turnaround in talent development.

Why purpose-driven firms are now more important than ever.

In this installment of the Harvard Business School Healthcare Alumni Association (HBSHAA) Q&A series, Michael Wong talks to Robert E. Siegel, lecturer in management at the Stanford Graduate School of Business, about determining the optimal combination of digital and physical assets for an S&P 500’s growth playbook.

Joseph A. DiAngelo, EdD, dean of the Erivan K. Haub School of Business at Saint Joseph’s University (SJU), discusses how the school’s programs reinforce real-world lessons and prepare younger generations to deal with a career environment in flux.

Ariel Katz, CEO and co-founder of H1, talks about how to find the right KOL for the right audience at the right time.

As emerging technologies are identified, C-suites need to determine how they might be pragmatically deployed as solutions to address their pain points, says IBM‘s Dr. Bernard S. Meyerson.

Alicia H. Munnell, Peter F. Drucker Professor of Management Sciences at Boston College’s Carroll School of Management, talks about building long-term financial health via career sustainability.

The MIT Institute for Work and Employment Research’s Dr. Thomas Kochan offers three key insights on engaging with AI and other digital solutions as they continue to transform the working environment.

Chris Doerr, Senior Vice President, Global Generic Sourcing, AmerisourceBergen, talks about the importance of companies taking an honest view of their current-state capabilities when embarking on the digital transformation journey.

Carolynn Johnson talks about changing the diversity, equity and includsion trends among the most progressive companies.

Landmark Bio CEO Ran Zheng talks about the value of collaborating with best-in-class partners.

Chairman of the Harvard China Fund, Dr. William C. Kirby, talks about the potential impact on multinational western pharma firms of disruption in China.

Dr. Randall N. Hyer, SVP Global Medical Affairs at Moderna, talks about the strategies that have helped the company grow from startup to multi-billion-dollar firm in a decade.

Insights from AmerisourceBergen EVP and Chief Strategy Officer, Leslie Donato.

Harvard Business School Professor Joseph B. Fuller talks about the future prospects for pharma sales forces as they face more restrictions on accessing their target physicians and looming concerns of automation.

Amgen board member and serial CEO Fred Hassan talks about the three levers Fortune 500 C-suites should consider as they position their firms from pilots to enterprise-wide digital transformation.

Dr. Andrew (Drew) Otoo talks about how pharma employees can elevate their own value propositions.

Dr. Amy P. Abernethy talks about her career moves from academia to industry to the US Food & Drug Administation.

Rajit Kamal, Vice President, Asia Pacific for DePuy Synthes, a Johnson & Johnson company, offers recommendations for those wishing to secure an expatriate assignment with their company.

Mark Altmeyer, CEO of Arvelle, offers three recommendations for big pharma executives who are considering making the leap to startups.

Todd Nichols, chief commercial officer of Alkermes, gives his top three recommendations for going all-in to digitally transform the frontline sales team.